Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and has the highest mortality rate among all solid tumors. It is characterized by early metastasis, and investigations of the molecular mechanisms underlying the progression and metastasis of NSCLC are urgently needed for the development of therapeutic targets. Here, we report that the transmembrane protein TMEM139 is significantly downregulated in NSCLC and that reduced expression of TMEM139 is correlated with a poor prognosis in NSCLC patients. Mechanistically, we found that TMEM139 directly interacts with E-cadherin at the plasma membrane and at focal adhesion sites. Moreover, TMEM139 can prevent the lysosomal degradation of E-cadherin, which inhibits epithelial-mesenchymal transition, migration and invasion of NSCLC cells both in vitro and in vivo. Our study not only expands our understanding of NSCLC metastasis but also provides a foundation to develop novel therapeutic strategies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207374 | PMC |
| http://dx.doi.org/10.1111/cas.15341 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world status of multimodal treatment of Stage IIIA-N2 non-small cell lung cancer in Japan: Results from the SOLUTION study, a non-interventional, multicenter cohort study.
Lung Cancer
November 2024
Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan. Electronic address:
Objectives: There is limited consensus on resectability criteria for Stage IIIA-N2 non-small cell lung cancer (NSCLC). We examined the patient characteristics, N2 status, treatment decisions, and clinical outcomes according to the treatment modality for Stage IIIA-N2 NSCLC in Japan.
Materials And Methods: Patients with Stage IIIA-N2 NSCLC in Japan were consecutively registered in the SOLUTION study between 2013 and 2014.
Deciphering the Significance of Platelet-Derived Chloride Ion Channel Gene (BEST3) Through Platelet-Related Subtypes Mining for Non-Small Cell Lung Cancer.
J Cell Mol Med
December 2024
Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of the University of Electronic Science and Technology of China, Chengdu, China.
This study investigates platelet-related subtypes in non-small cell lung cancer (NSCLC) and seeks to identify genes associated with prognosis, focusing on the clinical significance of the chloride ion channel gene BEST3. We utilised sequencing and clinical data from GEO, TCGA and the Xena platform, building a risk model based on genetic features. TCGA and GSE37745 served as training cohorts, while GSE50081, GSE13213, GSE30129 and GSE42127 were validation cohorts.
View Article and Find Full Text PDFGenetic variants of FER and SULF1 in the fibroblast-related genes are associated with non-small-cell lung cancer survival.
Int J Cancer
December 2024
Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA.
Article Synopsis
- A study analyzed 26,544 single nucleotide polymorphisms (SNPs) in 291 FRGs and identified 661 SNPs linked to overall survival (OS) in NSCLC patients, later validating these findings in a separate patient group.
- Two SNPs, FER rs7716388 A>G and SULF1 rs11785839 G>C, were found to be significantly associated with improved survival rates, suggesting that these genetic variants could serve as progn
Long-term outcomes of surgical treatment of non-small cell lung cancer with oligometastatic disease involving only the brain in the era of PET/CT.
J Cardiothorac Surg
December 2024
Department of General Thoracic Surgery, Osaka International Cancer Institute, 1,3,4: 3-1-69, Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
Background: The prognosis of patients with synchronous oligometastatic non-small cell lung cancer (NSCLC) has been improving owing to advancements in imaging techniques and new treatment approaches such as tyrosine kinase inhibitors. This study aimed to investigate the long-term outcomes, including the clinical course after recurrence, of patients with synchronous oligometastatic NSCLC with only brain metastases, treated with bifocal treatment.
Methods: We retrospectively analyzed 22 patients with clinical T1-4 and N0-1 NSCLC with synchronous brain metastases who were diagnosed by preoperative PET/CT and brain CT or MRI and underwent pulmonary resection for the primary site and surgery or radiation therapy for brain metastases at our institution from 2005 to 2019.
Predicting early stage lung cancer recurrence and survival from combined tumor motion amplitude and radiomics on free-breathing 4D-CT.
Med Phys
December 2024
Computer and Software Engineering Department, Polytechnique Montréal, Montréal, Quebec, Canada.
Background: Cancer control outcomes of lung cancer are hypothesized to be affected by several confounding factors, including tumor heterogeneity and patient history, which have been hypothesized to mitigate the dose delivery effectiveness when treated with radiation therapy. Providing an accurate predictive model to identify patients at risk would enable tailored follow-up strategies during treatment.
Purpose: Our goal is to demonstrate the added prognostic value of including tumor displacement amplitude in a predictive model that combines clinical features and computed tomography (CT) radiomics for 2-year recurrence and survival in non-small-cell lung cancer (NSCLC) patients treated with curative-intent stereotactic body radiation therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!